Clinical trials
Pulmonary Sarcoidosis clinical trials
Below are recruiting pulmonary sarcoidosis clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05890729RecruitingPhase 1/Phase 2
XTMAB-16 for lung sarcoidosis that still causes breathing trouble
This early-phase study tests XTMAB-16 to improve lung sarcoidosis in people who still have symptoms despite standard steroid-type treatment. It may help reduce inflammation and improve breathing, while also learning the safest dose and how the treatment works in humans.
Birmingham, AlabamaAges 18–80 - NCT06205121RecruitingPhase 2
Testing a new drug for active lung sarcoidosis
This study tests a new medication, OATD-01, for people with active sarcoidosis in their lungs. It aims to see how safe and effective the drug is and if it can improve symptoms.
Birmingham, AlabamaAges 18 years+ - NCT05746039RecruitingPhase 1/Phase 2
Testing semaglutide for advanced lung disease
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
Philadelphia, PennsylvaniaAges 18–80 - NCT06853834Recruiting
Comparing two biopsy methods for suspected sarcoidosis
This trial compares two ways of taking a lung tissue sample (cryo biopsy vs forceps biopsy) in people who may have sarcoidosis. The goal is to see which method is better at diagnosing the condition.
Lucknow, Uttar PradeshAges 18 years+ - NCT03755245Enrolling by invitation
Imaging study using a tracer to measure inflammation in joints and lungs
This trial tests how a radioactive imaging medicine (a tracer called 68Ga-DOTA-Siglec-9) spreads in the body and how well it shows inflammation. It includes both healthy volunteers and people with active rheumatoid arthritis, vasculitis, or pulmonary sarcoidosis to see if the scan matches disease activity.
TurkuAges 18–70 - NCT05841758RecruitingPhase 4
Hydroxychloroquine to reduce steroid use in sarcoidosis
This trial studies whether hydroxychloroquine can control extrapulmonary sarcoidosis (sarcoidosis outside the lungs) using less steroid treatment. It may help people who need systemic therapy for problems such as eyes, skin, bones, joints, nerves, ENT areas, or high calcium levels from sarcoidosis.
AvignonAges 18 years+ - NCT06479603RecruitingPhase 4
Nintedanib for lung scarring from sarcoidosis
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
ChandigarhAges Any age - NCT06848608Recruiting
Yoga vs. physical therapy for sarcoidosis fatigue
This study compares the benefits of yoga versus standard physical therapy for people with sarcoidosis who have lung involvement and fatigue. It aims to find which approach better helps manage symptoms and improve daily life.
Istanbul, MaltepeAges 18–75 - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT05567133Recruiting
Study markers that predict how sarcoidosis changes over time
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
Baltimore, MarylandAges 19 years+ - NCT00001532Recruiting
How Genes Affect Lung Disease Development
This research study examines how genetic factors contribute to various lung diseases, including alpha-1 antitrypsin deficiency, cystic fibrosis, and chronic obstructive pulmonary disease. Researchers want to understand why some people develop lung disease and how genetics plays a role, which may help improve treatment in the future.
Bethesda, MarylandAges 2–90 - NCT00470327Recruiting
Study of how interstitial lung disease naturally changes
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Chicago, IllinoisAges 18 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT07384897Recruiting
Immune cells in lung cancer and chronic lung disease
This study looks at how immune cells work in lung cancer and chronic lung diseases. It aims to find better ways to treat these conditions by studying immune cells from blood, bone marrow, or lung samples.
BrusselsAges Up to 80 years - NCT06573723Recruiting
Rare disease registry at Hospital Italiano
This study collects information from patients with certain rare diseases to better understand them. If you have one of these conditions and receive care at Hospital Italiano de Buenos Aires, you may be able to join.
Buenos Aires, Buenos AiresAges Any age - NCT06696027Recruiting
Loss of Y chromosome in autoimmune and lung disease
This study looks at how the loss of the Y chromosome in blood cells may be linked to autoimmune and lung diseases in older men. By joining, you help researchers understand this connection better.
Bonn, North Rhine-WestphaliaAges 50 years+
Hear when a new Pulmonary Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Pulmonary Sarcoidosis trials by city
Studies with a site in or near these metro areas.
Pulmonary Sarcoidosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for pulmonary sarcoidosis?
- Yes. Clin2 currently lists 16 recruiting pulmonary sarcoidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary sarcoidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary sarcoidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.